A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 4 Parts (Arms) where participants will receive ABBV-901, alone or in combination with the standard available therapy, bevacizumab. Around 219 participants will be enrolled in the study at approximately 75 sites around the world. In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901, alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901, combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901, combination with IV bevacizumab. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony zaawansowany rak jajnika, jajnika rurkowatego lub otrzewnej (wysoko zróżnicowany typ surowiczo-szpiczakowy)
- •Rak oporny na platynę lub niemożliwy do leczenia platyną (choroba postępiła w ciągu 6 miesięcy od ostatniej dawki platyny)
- •Wcześniejsze leczenie nowotworowe zgodne ze standardową opieką
- •Pacjenci z nowotworem opornym na platynę mogą mieć maksymalnie 2 wcześniejsze linie terapii
- •Dla wybranych pacjentów: zgoda na pobranie próbek nowotworu przed i podczas leczenia
✗ Disqualifies
- •Rak jajnika innych typów niż wysoko zróżnicowany surowiczo-szpiczakowy (np. jasnokomórkowy, śluzowy, niskozróżnicowany)
- •Wcześniejsze leczenie specjalnym lekiem łączącym przeciwciało z inhibitorem topoizomerazy
- •Ciężkie schorzenia płuc z zapaleniem (ILD lub zapalenie płuc wymagające sterydów)
- •Aktywne schorzenia płuc widoczne w badaniu CT przed rozpoczęciem leczenia
- •Stosowanie silnych leków wchodzących w interakcje z CYP3A w ciągu 14 dni przed badaniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (27)
City of Hope National Medical Center /ID# 281381
Duarte, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
Irvine, United States
Sarah Cannon Research Institute at HealthONE /ID# 278785
Denver, United States
University of Chicago Medical Center /ID# 278295
Chicago, United States
University Of Nebraska Medical Center /ID# 281020
Omaha, United States
NEXT Oncology - San Antonio /ID# 278606
San Antonio, United States
Start Mountain Region /ID# 278609
West Valley City, United States
Next Virginia /ID# 278607
Fairfax, United States
Blacktown Hospital /ID# 282426
Blacktown, Australia
Monash Health - Monash Medical Centre - Clayton /ID# 281468
Clayton, Australia
Peter MacCallum Cancer Centre. /ID# 281751
Melbourne, Australia
Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
Saint-Herblain, France
Centre Leon Berard /ID# 280575
Lyon, France
The Chaim Sheba Medical Center /ID# 278416
Ramat Gan, Israel
Rambam Health Care Campus /ID# 278418
Haifa, Israel
Hadassah Medical Center-Hebrew University /ID# 278420
Jerusalem, Israel
National Cancer Center Hospital East /ID# 278604
Kashiwa-shi, Japan
Saitama Medical University International Medical Center /ID# 278437
Hidaka, Japan
Shizuoka Cancer Center /ID# 278538
Sunto-gun, Japan
Unidade Local de Saude de Santa Maria /ID# 280296
Lisbon, Portugal
Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
Porto, Portugal
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
Majadahonda, Spain
Hospital Universitari Vall d Hebron /ID# 280442
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
Madrid, Spain
Hospital Universitario HM Sanchinarro /ID# 280439
Madrid, Spain
National Taiwan University Hospital /ID# 280701
Taipei, Taiwan
Taipei Veterans General Hospital /ID# 281349
Taipei, Taiwan
Trial contact
ABBVIE CALL CENTER
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.